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Background: Type I Bartter syndrome is a recessive human nephropathy caused by loss-of-function mutations in
the SLC12A1 gene coding for the Na+-K+-2Cl− cotransporter NKCC2. We recently established the mutant mouse line
Slc12a1I299F exhibiting kidney defects highly similar to the late-onset manifestation of this hereditary human disease.
Besides the kidney defects, low blood pressure and osteopenia were revealed in the homozygous mutant mice
which were also described in humans. Beside its strong expression in the kidney, NKCC2 has been also shown to be
expressed in other tissues in rodents i.e. the gastrointestinal tract, pancreatic beta cells, and specific compartments of
the ear, nasal tissue and eye.
Results: To examine if, besides kidney defects, further organ systems and/or metabolic pathways are affected by the
Slc12a1I299F mutation as primary or secondary effects, we describe a standardized, systemic phenotypic analysis of the
mutant mouse line Slc12a1I299F in the German Mouse Clinic. Slc12a1I299F homozygous mutant mice and Slc12a1I299F
heterozygous mutant littermates as controls were tested at the age of 4–6 months. Beside the already published
changes in blood pressure and bone metabolism, a significantly lower body weight and fat content were found as
new phenotypes for Slc12a1I299F homozygous mutant mice. Small additional effects included a mild erythropenic
anemia in homozygous mutant males as well as a slight hyperalgesia in homozygous mutant females. For other
functions, such as immunology, lung function and neurology, no distinct alterations were observed.
Conclusions: In this systemic analysis no clear primary effects of the Slc12a1I299F mutation appeared for the
organs other than the kidneys where Slc12a1 expression has been described. On the other hand, long-term effects
additional and/or secondary to the kidney lesions might also appear in humans harboring SLC12A1 mutations.
Keywords: Animal model, NKCC2, Systematic phenotype analysisBackground
The solute carrier family 12 member 1 (SLC12A1) gene
encodes the bumetanide-sensitive Na+-K+-2Cl− cotran-
sporter NKCC2. The electroneutral cotransporter NKCC2
belongs to the Na+-dependent subgroup of the solute
carrier 12 (SLC12) family of transporters. They are
membrane-bound proteins and mediate the electro-
neutral movement of Na+ and K+, tightly coupled to
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unless otherwise stated.outside to the inside of cells. NKCC2 is mainly expressed
in the kidney in the apical membrane of the cells of the
thick ascending limb of Henle’s loop (TALH) and of the
macula densa. It is responsible for one of the major salt
transport pathways in the kidney. It is involved in the
establishment and maintenance of salt accumulation in
the medulla which is required for the urine concentra-
tion mechanism and, thus, for the maintenance of body
salt and water homeostasis. In consequence, NKCC2
influences salt reabsorption, regulation of acid–base
and divalent mineral cation metabolism. Further, by
sensing luminal Cl− concentration to macula densa
cells, NKCC2 function is essential for renin release andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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matching glomerular filtration to tubular reabsorption.
NKCC2 is the main pharmacological target of loop di-
uretics like bumetanide or furosemide [1-3].
Several studies on the effect of sex steroids on NKCC2
abundance in rodent kidneys yielded variable results ([4]
and refs therein). Beside its strong expression in the kid-
ney, SLC12A1 in rodents was also shown to be expressed
in other tissues i.e. the gastrointestinal tract [5], pancreatic
beta cells [6], and specific compartments of the ear [7],
nasal tissue [8] and eye [9], although at lower levels when
compared to kidney.
In patients suffering from type I Bartter syndrome
(antenatal Bartter’s disease, hyperprostaglandin E syn-
drome), compound heterozygous or homozygous muta-
tions of the SLC12A1 gene (OMIM 601678) were
identified as cause [10]. To date, more than 70 causative
mutations of SLC12A1 were found in patients showing
lead symptoms of antenatal Bartter syndrome, Bartter
syndrome, and/or reduced blood pressure. Most muta-
tions are missense/nonsense mutations but splice site
mutations as well as small insertions/deletions also ap-
peared (http://www.hgmd.org). The mutations result in
decreased or absent activity of SLC12A1. NKCC2 acts
as dimer, in which the individual subunits transport Na+
independently, and there is a huge reserve capacity of
ion transport of NKCC2 in the kidney. In consequence,
heterozygous mutants show no obvious renal disease
phenotype due to the presence of a functional wild-type
allele which is sufficient to compensate for the functional
inactive mutant transcript. The hereditary recessive dis-
ease type I Bartter syndrome in homozygous mutant or
compound heterozygous mutant patients is characterized
by prenatal onset, a severe salt-wasting state with low
blood pressure, metabolic alkalosis with hypokalemia,
hyperreninemia, polyuria, hyperprostaglandinuria, and
often hypercalciuria. It is complicated by severe dehy-
dration episodes, recurrent vomiting, failure to thrive
and growth retardation. Clinical symptoms of type I
Bartter syndrome in humans often start to appear be-
fore birth, in the last trimenon of pregnancy, leading to
polyhydramnios and premature birth due to intrauter-
ine polyuria [2]. However, also patients exhibiting a
mild and/or late-onset manifestation of type I Bartter
syndrome as a result of a residual function of the mu-
tant NKCC2 transporter were described. This included
two siblings with the onset of clinical symptoms during
puberty [11] as well as other cases [12].
Recently, rare heterozygous missense mutations of
SLC12A1 were identified in a screen of members of the
Framingham Heart Study to act beneficially against the
risk of arterial hypertension and death due to cardio-
vascular disease. These mutant NKCC2 proteins exhib-
ited a reduced ion transport capacity, and this chronicreduction of NKCC2 function was discussed to result
in a lower blood pressure and decreased risk of hyperten-
sion in otherwise healthy individuals [13-16]. Reversely,
enhanced activity of NKCC2 has been linked to hyperten-
sion and hypertensive disorders in rodents and humans
([3] and refs. therein).
In mice, SLC12A1 has 1095 amino acids. Different full-
length splice variants of Slc12a1 are expressed. The main
isoforms A, B and F are derived by differential splicing of
one of three mutually exclusive exon cassettes which
encode the second transmembrane domain and parts of
the adjacent intracellular loop of the protein [17]. To
date, various Slc12a1 knockout mutant mouse models
have been published. Mice with a complete lack of the
NKCC2 cotransporter obtained by targeted disruption
of the Slc12a1 gene by deletion of promoter sequences
and exons 1–3 maintained on the 129/SvEv inbred gen-
etic background were born normally, but died within
the first two weeks postpartum due to severe renal fail-
ure and metabolic alterations [18]. Two isoform-specific
mouse knockouts for SLC12A1 were generated by intro-
ducing premature stop codons into the mutually exclusive
exon cassettes in the mixed 129/SvEv and C57BL/6
genetic background. Both mouse lines deficient in either
NKCC2 isoform A or B exhibited minor phenotypic kid-
ney alterations [19,20].
In the phenotype-based Munich ENU mouse mutagen-
esis project using C3HeB/FeJ (C3H) inbred mice as gen-
etic background, several mutant lines were established
showing increased plasma urea levels as a parameter indi-
cative of kidney disease [21]. One line showed the muta-
tion Slc12a1I299F which affects all full-length isoforms of
the gene. Homozygous mutant mice are viable and repro-
duce normally. The markedly increased plasma urea con-
centration is not due to a general renal failure as plasma
creatinine is only slightly elevated, and the creatinine
clearance is higher than in wild-type mice. Homozygous
mutants show a severe defect in their ability to concen-
trate urine, leading to increased urine excretion and water
consumption. In addition, prostaglandin E as well as cal-
cium and magnesium excretion are markedly increased,
and the fractional excretion of uric acid is reduced. In
addition, homozygous mutants exhibit hypotension and
osteopenia. Thus, they exhibit a late-onset manifestation
of type I Bartter syndrome and may represent a new
model for the study of this human disease [22]. Heterozy-
gous mutants of line Slc12a1I299F showed only slight devi-
ations and are highly similar to the wild-type phenotype
[22]. This was also observed in Slc12a1 heterozygous
knockout mice [23].
To examine if further organ systems and/or metabolic
pathways are affected as primary or secondary effects,
we describe a standardized, systemic phenotypic analysis
of the mutant mouse line Slc12a1I299F in the German
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vital organ systems and functions. As nephropathy-
causing reduced NKCC2 ion transport capacity occurs
if both alleles are mutated, homozygous mutant mice
were analyzed and compared to healthy heterozygous
mutant controls.
Methods
The recessive mutant line Slc12a1I299F was established
in the Munich ENU mouse mutagenesis project using
C3HeB/FeJ (C3H) inbred mice as genetic background
[24]. Maintenance of the line comprised the repeated
backcross to C3H wild-type mice leading to the subse-
quent loss of non-causative ENU mutations that were not
linked to the Slc12a1 mutation. The systemic, comprehen-
sive phenotypic analysis was carried out in the German
Mouse Clinic at the Helmholtz Zentrum München by
using standardized examination protocols (http://www.
mouseclinic.de). The analysis covers over 300 parameters
in the areas of allergy, behavior, bone and cartilage, cardio-
vascular analysis, clinical chemistry, energy metabolism,
eye analysis and vision, immunology, lung function, mo-
lecular phenotyping, neurology, nociception, pathology,
and steroid metabolism [25-27].
Homozygous mutant mice and heterozygous mutant
littermates as controls were tested at defined time
points in the German Mouse Clinic (see Additional file 1:
Table S1). The analyses used defined numbers of animals
(stated in the text of the respective Results section) out of
a cohort of 15–17 animals per sex and genotype. Further-
more, an additional cohort of homozygous mutant mice
and wild-type littermates were used for selected analyses
like clinical chemistry on further age groups [22].
Mouse husbandry was done under a continuously
controlled specific pathogen-free (SPF) hygiene stand-
ard according to the FELASA recommendations (http://
www.felasa.eu) [28].
If not otherwise stated, statistical analysis of data was
carried out by Student’s t-test. Data are shown as mean
± standard error of the mean. Significant differences are
indicated for P < 0.05, 0.01, and 0.001.
Ethics statement
Mouse husbandry and all tests were carried out under
the approval of the responsible animal welfare authority
(Regierung von Oberbayern, Germany).
Results
Phenotypic analysis in the German Mouse Clinic
The recessive mutant line Slc12a1I299F was established
by the detection of increased plasma urea levels in
homozygous mutant mice. Plasma urea levels of hetero-
zygous mutants and C3H wild-type controls were simi-
lar, and therefore heterozygous mutants were defined ashealthy without nephropathy [21,22]. As disease-causing
reduced NKCC2 ion transport capacity occurs if both
alleles are mutated, homozygous mutant mice as well as
heterozygous mutant littermates as controls were tested
in the German Mouse Clinic (see Additional file 1:
Table S1).
Phenotypic analysis of mutant mice in the German
Mouse Clinic aims at collecting and delivering with free
access comprehensive phenome data of a high number
of mutant mouse lines in a standardized manner. The
phenotype report of mutant line Slc12a1I299F (see line
“HST009”) is deposited online (http://146.107.35.38/
phenomap/jsp/annotation/public/phenomap.jsf ).
Additional clinical chemistry analysis
Blood data of 3-month-old homozygous mutants, hetero-
zygous mutants and wild-type controls of line Slc12a1I299F
(n = 10 per genotype and sex) were previously described.
They were confirmed by the analysis of 6-month- and 1-
year-old mice [22]. The additional analysis of the clinical-
chemical and hematological parameters of homozygous
mutants vs. heterozygous mutants as controls (n = 15 per
genotype and sex) at the age of 17 weeks revealed com-
parable results. Thus, homozygous mutants of both sexes
showed increased values for calcium, creatinine, urea
(127 ± 3 mg/dl vs. 61 ± 2 mg/dl in males, 92 ± 4 mg/dl
vs. 54 ± 2 mg/dl in females; P < 0.001), alkaline phosphat-
ase (93 ± 4 U/l vs. 84 ± 2 U/l in males, P < 0.05; 120 ± 4 U/l
vs. 109 ± 4 U/l in females, not significant; similar but not
significant differences were observed in 8–10 mice per
genotype and sex as a subgroup of the previously tested
mice at the age of 22 weeks), alpha amylase and lipase, as
well as decreased values for chloride, whereas the levels
for sodium, potassium, inorganic phosphate, total protein,
uric acid, cholesterol, triglycerides, glucose, lactate, creat-
ine kinase, alanine aminotransferase (ALT) and aspartate
aminotransferase (AST) were not significantly altered. In
the hematological analysis at both ages (17 weeks and
22 weeks), male homozygous mutants showed increased
values for the white blood cell count, as well as decreased
values for the red blood cell count, platelet count,
hemoglobin and hematocrit, whereas female homozy-
gous mutants showed no significant differences (Table 1).
Thus, a slight erythropenia was revealed in the male
homozygous mutants.
Additional analysis of cardiovascular function
Analysis of cardiovascular function of 3-month-old mice
of line Slc12a1I299F was previously described. Compared
to wild-type controls, mean arterial blood pressure as
well as systolic and diastolic pressures were significantly
decreased in homozygous mutants. Heart rate did not dif-
fer significantly between genotypes. In addition, plasma
concentration of the N-terminal fragment of the pro-atrial
Table 1 Hematological analysis of line Slc12a1I299F
Males Females
Parameter Homozygous mutants Heterozygous mutants Homozygous mutants Heterozygous mutants
WBC (103/μl) 8.4 ± 0.9a 6.4 ± 0.3 7.0 ± 0.2 6.8 ± 0.5
RBC (106/μl) 8.8 ± 0.1a 9.1 ± 0.1 9.0 ± 0.2 9.0 ± 0.1
PLT (103/μl) 680 ± 14c 760 ± 12 671 ± 21 704 ± 22
HGB (g/dl) 14.2 ± 0.2b 14.9 ± 0.1 14.8 ± 0.3 14.5 ± 0.2
HCT (%) 43.5 ± 0.5b 46.1 ± 0.4 45.3 ± 0.8 45.0 ± 0.4
MCV (fl) 49.5 ± 0.2b 50.4 ± 0.2 50.4 ± 0.3 50.1 ± 0.2
MCH (pg) 16.1 ± 0.1 16.3 ± 0.1 16.4 ± 0.1 16.1 ± 0.1
MCHC (g/dl) 32.6 ± 0.2 32.3 ± 0.1 32.7 ± 0.2 32.3 ± 0.1
WBC, white blood cell count; RBC, red blood cell count; PLT, platelet count; HGB, hemoglobin; HCT, hematocrit; MCV, mean corpuscular volume; MCH, mean
corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration.
22-week-old mice were tested. No. per genotype and sex: n = 8–10. Data are presented as mean ± standard error of mean. Student’s t-test vs. heterozygous
mutants as controls: a P < 0.05, b P < 0.01, c P < 0.001.
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homozygous mutants of both genders. ANP is a cardiac
hormone predominantly secreted by atrial myocytes in re-
sponse to cardiac filling pressures. Plasma renin concen-
tration in homozygous mutant mice was significantly
lower than in wild-type littermate controls [22].
Additional analysis of 19-week-old homozygous mutants
vs. heterozygous mutants as controls (n = 9–11 mice per
genotype and sex) for mean arterial blood pressure as well
as systolic pressure and diastolic pressure showed the
same tendency without reaching statistical significance
(Table 2). Compared to a cohort of C3H mice taken from
a different breeding colony and maintained under different
housing conditions (systolic pressure: 127 ± 2 mm Hg in
males and 124 ± 2 mm Hg in females; diastolic pressure:
112 ± 2 mm Hg in males and 109 ± 3 mm Hg in females),
the mutants showed low blood pressure values.
In addition, electrocardiography was done in the identi-
cal 20-week-old mice to analyze quantitative (PQ interval,
P-wave duration, QRS-complex duration, QT interval, RR
interval, heart rate, JT interval, ST interval, Q amplitude,
R amplitude, S amplitude, QRS amplitude) as well as quali-
tative parameters (arrhythmias). No significant genotype-
specific phenotype was revealed between homozygous
mutant mice and heterozygous mutant littermates as
controls (not shown).Table 2 Cardiovascular analysis of line Slc12a1I299F
Males
Parameter Homozygous mutants Heterozyg
Systolic pressure (mm Hg) 103 ± 3 107 ± 2
Diastolic pressure (mm Hg) 86 ± 3 89 ± 2
Mean arterial pressure (mm Hg) 91 ± 3 94 ± 2
Pulse (bpm) 561 ± 15a 602 ± 7
19-week-old mice were tested. No. per genotype and sex: n = 9–11. Data are presen
mutants as controls: a P < 0.05.Additional analysis of dysmorphology
In addition to the previously published differences in
bone metabolism in 9 month-old homozygous mutants
[22], systemic morphological investigation via visual in-
spection and X-ray analysis according to standardized
protocols were carried out. Fifteen mice of each geno-
type and sex were analyzed by morphological inspection
at the age of 14 weeks. The systematic morphological in-
vestigation via visual inspection (growth/weight/body size,
eye, coat, skin, vibrissae, extremities including limbs, digits
and tail, teeth, ears, musculature, behavior/movement,
feeding/drinking, respiratory system, other conspicuous
phenotypes) found genotype-specific differences for two
parameters. Compared to the heterozygous mutant con-
trols, 10 of the 15 female homozygous mutants analyzed
showed a pale colour of the maxillary incisors, which
might reflect a mineralization defect via deposition of
calcium salts. This was not observed in male homozy-
gous mutants. In addition, two of the 15 male and all 15
female homozygous mutants showed a pale colour of
the urine. All other parameters of the visual inspection
were inconspicuous in homozygous mutant mice com-
pared to heterozygous mutant littermates as controls.
Hearing ability was examined by the clickbox test
using a sound of 20 kHz. In males, all 15 homozygous
mutants and all 15 heterozygous mutants showed aFemales
ous mutants Homozygous mutants Heterozygous mutants
105 ± 3 111 ± 3
90 ± 2 93 ± 3
95 ± 2 99 ± 3
615 ± 11 614 ± 20
ted as mean ± standard error of mean. Student’s t-test vs. heterozygous
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and 14 heterozygous mutants showed a normal reaction,
whereas 1 mouse each of the groups of homozygous mu-
tants and heterozygous mutants showed a retarded reac-
tion. Thus, no genotype-specific phenotype was found
between homozygous mutants and heterozygous mutants
as controls.
Ten males each of homozygous mutants and heterozy-
gous mutants as well as 11 female homozygous mutants
and 9 female heterozygous mutants entered the bone
density and X-ray analysis at the age of 21 weeks. X-ray
analysis of the skeleton (skull shape, mandibles, maxilla,
teeth, orbit, number of vertebrae, vertebrae shape, number
of ribs, rib shape, scapula, clavicle, pelvis, femur shape,
tibia, fibula, humerus, ulna, radius, number of digits, com-
pleteness of digits, joints) found no genotype-specific dif-
ferences between homozygous mutants and heterozygous
mutants.
In the dual energy X-ray absorption (DXA) analysis of
bone- and weight-related parameters at the age of 21 weeks,
bone mineral density (BMD) and bone mineral content
(BMC) were decreased in homozygous mutants, however
BMD related to the body weight (sBMD) was not sig-
nificantly changed. Body weight and fat content were
significantly decreased in homozygous mutants, and
lean content was increased. Differences between homo-
zygous mutants and heterozygous mutant controls in
bone parameters might be due to changes in body com-
position and thus be secondary effects (Table 3). Add-
itional analyses of 9-month-old mice have been already
published and showed the significant reduction of the
femoral cortical bone mineral density in homozygous
mutants compared with wild-type mice, indicating
osteopenia [22].Table 3 Dual energy X-ray absorption (DXA) analysis of bone
age of 21 weeks
Males
Parameter Homozygous mutants Heterozygo
Body length (cm) 10.3 ± 0.1 10.3 ± 0.1
Body weight (g) 33.3 ± 0.5c 40.0 ± 1.0
Lean mass (units) 23.0 ± 1.0b 17.1 ± 1.3
Lean content (units × 100/g) 69.0 ± 2.7c 42.7 ± 3.2
Fat mass (units) 6.7 ± 0.9c 18.6 ± 1.4
Fat content (units × 100/g) 20.2 ± 2.6c 46.4 ± 3.1
BMD (mg/cm2) 67 ± 1c 75 ± 1
sBMD (10−3 × cm−2) 2.0 ± 0.1 1.9 ± 0.1
BMC (mg) 890 ± 45c 1306 ± 67
Bone content (%) 2.7 ± 0.1a 3.3 ± 0.2
BMC, bone mineral content; BMD, bone mineral density; sBMD, specific bone miner
No. per genotype and sex: n = 9–11. Data are presented as mean ± standard error o
bP < 0.01, cP < 0.001.Eye analysis
Slit lamp biomicroscopy, funduscopy and laser interfer-
ence biometry (n = 15 per genotype and sex) were car-
ried out at 16 weeks of age to analyze for anterior
segment abnormalities, posterior segment abnormalities,
and axial eye length abnormalities, respectively. Slit lamp
biomicroscopy detected no abnormalities like nuclear
flecks, corneal erosions or microphthalmia. Funduscopy
also detected no abnormalities like microflecks or vessel
alterations. Pigment patches and vessel attenuation were
found in all mice of all four groups. Homozygous mutants
vs. heterozygous mutants as controls also showed no dif-
ference in the axial eye length (3.6 ± 0.004 mm vs. 3.6 ±
0.004 mm in males, 3.6 ± 0.007 mm vs. 3.6 ± 0.004 mm in
females) and in the ratio of axial eye length and body
length (0.035 ± 0.0002 vs. 0.035 ± 0.0002 in males, 0.035 ±
0.0002 vs. 0.035 ± 0.0002 in females). Thus, no genotype-
specific differences were found between homozygous mu-
tants and heterozygous mutant controls. Line Slc12a1I299F
is based on the C3H genetic background and therefore
showed the typical phenotype of retinal degeneration of
C3H mice leading to blindness in the early phase of life in
all mice irrespective of the genotype for Slc12a1. There-
fore, no vision analysis was carried out.
Energy metabolism
Homozygous mutants and heterozygous mutants as con-
trols at the age of 17 weeks exhibited similar plasma chol-
esterol (154 ± 4 mg/dl vs. 165 ± 5 mg/dl in males, 117 ±
4 mg/dl vs. 118 ± 3 mg/dl in females) and triglycerides
(349 ± 32 mg/dl vs. 427 ± 28 mg/dl in males, 288 ± 26 mg/dl
vs. 256 ± 19 mg/dl in females) values.
Metabolic analysis was carried out with 23- to 24-week-
old mice (n = 7 per genotype and sex) under ad libitum- and weight-related parameters in line Slc12a1I299F at the
Females
us mutants Homozygous mutants Heterozygous mutants
10.3 ± 0.1 10.4 ± 0.1
32.1 ± 1.1a 35.9 ± 1.4
18.7 ± 1.0b 14.1 ± 0.9
59.4 ± 4.4b 40.1 ± 3.7
9.7 ± 1.8b 17.7 ± 1.9
29.0 ± 4.4b 48.2 ± 3.6
70 ± 1b 75 ± 1
2.2 ± 0.04 2.1 ± 0.1
966 ± 68a 1234 ± 67
3.0 ± 0.1b 3.4 ± 0.1
al density.
f mean. Student’s t-test vs. heterozygous mutants as controls: aP < 0.05,
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exhibited significantly less body weight than heterozygous
mutants but assimilated comparable amounts of energy.
In total, no clear differences in addition to the altered
body weight parameters were observed for homozygous
mutant mice compared to heterozygous mutant mice.
Immunology
Peripheral blood leukocytes were isolated and viable
cells were subsequently analyzed for the identification of
main cell populations (B cells, T cells, granulocytes, NK
cells) und subpopulations. Plasma antibody levels were
determined simultaneously in the same samples (Table 5).
The initial analysis of homozygous mutants vs. heterozy-
gous mutant controls at the age of 17 weeks revealed
some changes affecting male homozygous mutants. How-
ever, they were not found in blood samples from the same
cohort of mice at the age of 22 weeks (not shown). Also
no changes in autoantibodies (anti-DNA antibodies,
rheumatoid factor) were observed (not shown).
The detailed examination of cellular subsets bearing
activation/memory markers in blood samples of homo-
zygous mutants and heterozygous mutant controls at the
age of 17 weeks and 22 weeks showed an increase of
activated/memory CD4+CD62Llow helper T cells (P < 0.05
at the age of 17 weeks and 22 weeks) and CD8+ CD62Llow
cytotoxic T cells (P < 0.05 at the age of 22 weeks) in
homozygous mutant mice. Thus, this mild but steadily
expressed phenotype was confirmed (not shown) which
fits to clinical data from human patients with chronic
renal failure, where changes in memory T cells bearing
the CD62L marker are well described [29]. It has been
established for humans that changes affecting frequen-
cies of leukocyte subsets are secondary effects of renal






Body weight (g) 33.0 ± 0.4 4
Rectal body temperature (°C) 36.2 ± 0.04 3
Food intake (g/day) 3.7 ± 0.2 4
Energy uptake (kJ/day) 66.2 ± 4.2 7
Energy uptake / body weight (kJ/g/day) 2.0 ± 0.1 1
Feces production (g/day) 0.91 ± 0.04 0
Energy content of feces (kJ/g) 15.3 ± 0.1 1
Metabolized energy (kJ/day) 51.3 ± 4.2 5
Metabolized energy / body weight (kJ/g/day) 1.55 ± 0.12 1
Food assimilation coefficient (%) 77.0 ± 1.7 7
23-24 week-old mice (n = 7 per genotype and sex) were tested under ad libitum co
homozygous mutants (males and females) vs. heterozygous mutants (males and femLung function
Spontaneous breathing patterns during sleep, rest and
activity were analyzed in 5–6 mice per genotype and sex
at 21 weeks of age by whole body plethysmography
(Table 6). Homozygous mutant males exhibited signifi-
cantly less body weight than heterozygous mutant males
as controls, whereas homozygous mutant females showed
analogous results by tendency. The mean of all breathing
frequencies (mean f) measured during the 40-minute
examination period was calculated as a general parameter
to assess whether the duration of rest and activity was
similar in all groups. It did not differ between homozygous
mutants and heterozygous mutants. Specific tidal volumes
and specific minute ventilations (sTV and sMV) during
sleep, rest and activity, respectively, were calculated by re-
lating the absolute values to the body weight of the ani-
mals. Overall, observed differences between homozygous
mutants and heterozygous mutant controls were within
the physiological ranges and of minor relevance. This was
confirmed by comparison of the data to a cohort of C3H
mice taken from a different breeding colony and main-
tained under different housing conditions (not shown).
Therefore it was concluded that the mutation Slc12a1I299F
does not affect the respiratory system.
Neurology
Basic neurological functions were tested in 16-week-old
mice (n = 15 per sex and genotype) by modified SHIRPA
and forelimb grip strength analysis for the assessment of
muscular function.
The modified SHIRPA protocol is a semi-quantitative
screening method for the overall qualitative analysis of
abnormal phenotypes in mice and includes 23 test param-
eters each contributing to the overall assessment of gen-








0.0 ± 1.1 31.7 ± 1.3 36.2 ± 1.3 c
6.3 ± 0.1 36.7 ± 0.1 36.6 ± 0.1
.1 ± 0.1 3.9 ± 0.2 3.9 ± 0.1
2.6 ± 1.6 69.9 ± 4.0 70.1 ± 2.0
.8 ± 0.1 2.2 ± 0.1 2.0 ± 0.1 a
.91 ± 0.05 0.81 ± 0.08 0.93 ± 0.02
5.4 ± 0.1 15.3 ± 0.1 15.2 ± 0.1
7.5 ± 1.7 56.4 ± 3.5 54.9 ± 1.7
.45 ± 0.06 1.78 ± 0.09 1.53 ± 0.07
9.1 ± 1.1 80.7 ± 1.8 78.3 ± 0.4
nditions. Data are presented as mean ± standard error of mean. Student’s t-test:
ales) as controls: a, P < 0.05; c, P < 0.001.
Table 5 Immunology analysis of line Slc12a1I299F
Males Females
Parameter Homozygous mutants Heterozygous mutants Homozygous mutants Heterozygous mutants
CD3+ 38.8 ± 1.8 35.1 ± 2.3 37.4 ± 1.7 36.1 ± 1.3
CD4+ 25.7 ± 1.2 22.9 ± 1.6 23.3 ± 1.3 21.9 ± 1.1
CD8β+ 22.2 ± 0.9 20.6 ± 1.6 22.9 ± 1.0 22.4 ± 1.0
CD19+ 28.9 ± 1.1 31.1 ± 1.1 30.3 ± 1.1 29.6 ± 1.0
CD19+CD5+ 3.5 ± 0.2 3.3 ± 0.2 3.9 ± 0.2 3.5 ± 0.1
CD19+CD5− 96.4 ± 0.2 96.5 ± 0.2 95.9 ± 0.2 96.3 ± 0.1
CD49b+ 29.9 ± 1.5b 23.0 ± 1.6 28.8 ± 1.9 27.3 ± 1.6
Gr1+ 31.7 ± 0.8 37.0 ± 2.1 27.0 ± 1.4 30.0 ± 1.3
IgA 445 ± 14 453 ± 40 475 ± 18 478 ± 17
IgG1 130 ± 12 158 ± 17 174 ± 13 211 ± 20
IgG2a 385 ± 25 476 ± 34 558 ± 43 518 ± 35
IgG2b 94 ± 4a 147 ± 21 175 ± 10 165 ± 8
IgG3 324 ± 25a 424 ± 18 465 ± 25 408 ± 22
IgM 1338 ± 142 1782 ± 275 1623 ± 164 1590 ± 195
Data are frequencies of main leukocyte subsets in blood (%) and concentration (μg/ml) of antibodies of different isotypes in plasma.
17-week-old mice were tested. No. per genotype and sex: n = 15. Data are presented as mean ± standard error of mean. Student’s t-test vs. heterozygous mutants
as controls: aP < 0.05, bP < 0.01.
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cantly decreased in homozygous mutants vs. heterozygous
mutants as controls (31.2 ± 0.4 g vs. 35.6 ± 0.7 g in males,
and 30.7 ± 0.9 g vs. 33.2 ± 0.9 g in females; P < 0.05). All
other SHIRPA parameters (body position, tremor, pal-
pebral closure, coat appearance, whiskers, lacrimation,
defecation, transfer arousal, locomotor activity, gait,
tail elevation, touch escape, positional passivity, skin
colour, trunk curl, limb grasping, pinna reflex, corneal
reflex, righting reflex, contact righting, evidence ofTable 6 Analysis of lung function of line Slc12a1I299F
Males
Parameter Homozygous mutants Heterozygous
Body weight (g) 33.6 ± 0.8 a 38.9 ± 1.5
Mean f (1/min) 334 ± 19 354 ± 7
Sleep f (1/min) 125 ± 5 b 149 ± 4
Rest f (1/min) 277 ± 19 297 ± 4
Activity f (1/min) 468 ± 6 474 ± 11
Sleep sTV (μl/g) 8.4 ± 0.2 7.3 ± 0.4
Rest sTV (μl/g) 6.0 ± 0.2 5.5 ± 0.3
Activity sTV (μl/g) 5.8 ± 0.2 5.5 ± 0.4
Sleep sMV (ml/min/g) 1.0 ± 0.04 1.1 ± 0.1
Rest sMV (ml/min/g) 1.5 ± 0.1 1.5 ± 0.1
Activity sMV (ml/min/g) 2.7 ± 0.1 2.5 ± 0.2
f, respiratory rates; mean f (1/min), the mean of all breathing frequencies (mean f) m
parameter to assess whether the duration of rest and activity was similar in all grou
calculated by relating the absolute values to the body weight of the animals.
21-week-old mice were tested. No. per genotype and sex: n = 5–6. Data are present
mutants as controls: aP < 0.05, bP < 0.01.biting, vocalisation) were without significant alterations in
homozygous mutants vs. heterozygous mutant controls.
Also forelimb grip strength did not differ between both
genotypes.
Nociception
Analysis of nociception was carried in 18-week-old mice
by using the hot plate assay at 50°C for the detection of
altered pain response. The reactions due to thermal pain
by shaking and licking of the hind paws were measuredFemales
mutants Homozygous mutants Heterozygous mutants
34.8 ± 1.4 36.3 ± 2.0
355 ± 23 308 ± 25
130 ± 7 128 ± 6
293 ± 11a 251 ± 13
460 ± 5 426 ± 20
9.4 ± 0.5 8.5 ± 0.6
6.5 ± 0.3 6.3 ± 0.3
6.2 ± 0.2a 5.5 ± 0.2
1.2 ± 0.04 1.1 ± 0.1
1.8 ± 0.1b 1.4 ± 0.04
2.8 ± 0.1b 2.3 ± 0.1
easured during the 40-minute examination period was calculated as a
ps; sTV, specific tidal volumes and sMV, specific minute ventilations were
ed as mean ± standard error of mean. Student’s t-test vs. heterozygous
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controls (latency in seconds for shacking of hind paws:
46.5 ± 2.7 vs. 46.5 ± 2.7 in males, 35.3 ± 2.6 vs. 43.1 ± 2.8
in females (P < 0.05); latency in seconds for licking of
hind paws: 51.6 ± 2.5 vs. 50.3 ± 2.5 in males, 39.8 ± 2.4
vs. 48.6 ± 2.7 in females (P < 0.05); n = 10–15 per geno-
type and sex). Thus, slight differences were found in
homozygous mutant females showing mild hyperalgesia
by a decreased latency period.
Discussion
Slc12a1I299F mutant mice were examined using a systemic
and standardized, comprehensive phenotypic analysis at
the age of 14–26 weeks. In humans, nephropathy-causing
reduced ion transport capacity of the NKCC2 dimers oc-
curs if both alleles are mutated [2], and the recessive char-
acter of Slc12a1 mutations to cause renal disease has been
shown in knockout mice [23] as well as in our previous
publication of line Slc12a1I299F [22]. Thus, Slc12a1I299F
homozygous mutants were examined and Slc12a1I299F
heterozygous mutant littermates were used as control
animals. NKCC2 is a 12-transmembrane cotransporter.
The point mutation of line Slc12a1I299F leads to the
amino acid exchange I299F that is located at the first
position of the fourth transmembrane-spanning do-
main. This region is well conserved among mammalian
species [22]. In humans, disease-causing mutations are
described in this region, e.g. affecting the amino acid
directly before I299 (http://www.hgmd.org). The most
obvious phenotype of Slc12a1I299F homozygous mu-
tants was a severe defect in urine concentrating ability,
leading to increased urine excretion and water con-
sumption. In addition, homozygous mutants exhibited
hypotension and osteopenia due to their impaired elec-
trolyte homeostasis [22].
The systemic and standardized phenotypic analysis of
line Slc12a1I299F in the German Mouse Clinic is described
to evaluate further primary effects of this mutation as
NKCC2 has been shown in rodents to be expressed in
other tissues i.e. the gastrointestinal tract [5], pancreatic
beta cells [6], and specific compartments of the ear [7],
nasal tissue [8] and eye [9]. In addition to the cardiovascu-
lar and skeletal alterations, the impaired kidney function
may also lead as secondary consequences to alterations in
hematological parameters, chronic inflammation of the
gastrointestinal system, or uremic effects on the central
nervous system. Furthermore, several studies on the effect
of sex steroids on NKCC2 in rodent kidneys yielded vari-
able results ([4] and refs therein), therefore sex-specific
alterations may occur in the line Slc12a1I299F.
The analyses of the clinical chemistry, cardiovascular
function and dysmorphology at additional time points
supported the already published data of line Slc12a1I299F
[22]. The hematological analyses at the age of 17 and22 weeks revealed a mild erythropenic anemia in male
but not female homozygous mutants. One possible ex-
planation is that this might occur as a secondary effect
due to the impaired kidney function which might also
lead to a reduced erythropoietin production. Although
the homozygous mutant mice exhibited severe polyuria,
there was no hint for a general dehydration of the mice
as it has been described in Slc12a1 homozygous knock-
out mice at the perinatal stage [18]. The heterozygous
mutant animals showed no obvious differences com-
pared to a cohort of C3H wild-type mice from the same
facility. Compared to the hypotension already described
in 3-month-old Slc12a1I299F homozygous mutants, 19-
week-old homozygous mutants showed the same tendency
of the data but without reaching statistical significance.
Lung function data of homozygous mutants showed no
obvious alterations.
In the morphological analysis, genotype-specific alter-
ations were found. The maxillary incisors of most female
homozygous mutants showed a pale colour, and the urine
colour of female homozygous mutants was pale. To date,
there is no published information regarding the expression
of Slc12a1 in teeth. At the age of 21 weeks, body weight
and fat content were significantly lower in homozygous
mutants. The lower level of body weight was confirmed in
further analyses in the German Mouse Clinic at 21 and
23–24 weeks of age. Homozygous mutants only exhibited
83-86% (males) and 88-96% (females) of the body weight
of the heterozygous mutant controls. A lower body weight
has been already found by tendency in 3-month-old
Slc12a1I299F homozygous mutants [22]. Analysis of the
energy metabolism at the age of 23–24 weeks under ad
libitum conditions revealed a significantly lower body
weight of homozygous mutant mice, but no clear add-
itional differences. Thus, the metabolic and thermoregula-
tory properties have to be clarified in further studies.
Analyses of the sensory organs showed no obvious effect
of the mutation on hearing ability, olfaction or on eye
development in homozygous mutants vs. heterozygous
mutant controls.
The immunology analysis revealed mild deviations in
the homozygous mutants, most likely as a secondary ef-
fect of the primary renal impairment. No indications
were observed for the appearance of major inflammatory
processes in the mutant mice. In the allergy analysis,
also no genotype-specific differences were found (data
not shown). The neurological results of homozygous
mutants were within the physiological range of C3H
mice and did not permit to define an altered behavioral
pattern for the homozygous mutant animals. Mental re-
tardation has been described in severely affected human
patients [10]. The analysis of nociception by thermal
pain at the age of 18 weeks found slight differences in
homozygous mutant females showing mild hyperalgesia.
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Slc12a1 is mainly expressed in the kidney, and amino
acid-changing mutations of SLC12A1 in humans lead to
the severe defect in the ability to concentrate urine. The
systemic phenotypic analysis of Slc12a1I299F homozygous
mutant mice vs. heterozygous mutant mice as controls
on the C3H inbred genetic background at the age of 14–
26 weeks reproducibly revealed the polyuric nephropathy,
impaired electrolyte homeostasis, hypotension and osteo-
penia. Slc12a1I299F homozygous mutant mice showed a
significantly lower body weight and fat content. This
might reflect a decreased activity of the mutant SLC12A1
in the gastrointestinal tract and/or pancreatic beta cells
and/or might be a secondary effect of the kidney disease.
No obvious effect of the mutation was found on hearing
ability, olfaction or on eye development. The other ana-
lyses showed small additional effects. Thus, depending on
the genetic background, long-term effects additional and/
or secondary to the kidney lesions might also appear in
humans harboring SLC12A1 mutations.
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